评价BP1001(一种脂质体Grb2反义寡核苷酸)联合达沙替尼(Das)在费城染色体阳性(Ph+)患者中的安全性、药代动力学和疗效的Ib/IIa期单臂、开放标签临床试验

描述

Ib期研究的主要目标是确定BP1001联合达沙替尼在费城染色体阳性(Ph+)慢性粒细胞白血病(CML)患者(包括初始酪氨酸激酶抑制剂(TKI)失败的慢性期患者)中的剂量限制毒性(DLT)和最大耐受剂量(MTD)。therapy, accelerated or blast phase, Ph+ Acute Myeloid Leukemia (AML) or High-risk Ph+ Myelodysplastic Syndrome (MDS). The primary objective of the Phase IIa study is to assess the efficacy of the combination of BP1001 and dasatinib in patients with Ph+ CML, Ph+AML, or high-risk Ph+ MDS.

资源和链接

电话:1 - 877 - mda - 6789

NCT号:NCT02923986